Nephrotoxicity in survivors of Wilms' tumours in the North of England

por Bailey, S, Roberts, A, Brock, C, Price, L, Craft, A W, Kilkarni, R, Lee, R E J, Skillen, A W, Skinner, R
Publicado 2002

Protracted infusional 5-fluorouracil plus high-dose folinic acid combined with bolus mitomycin C in patients with gastrointestinal cancer: a phase I/II dose escalation study

por Hartmann, J T, Oechsle, K, Quietzsch, D, Wein, A, Hofheinz, R D, Honecker, F, Nehls, O, Köhne, C-H, Käfer, G, Kanz, L, Bokemeyer, C
Publicado 2003

Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy

por Ray-Coquard, I, Borg, C, Bachelot, Th, Sebban, C, Philip, I, Clapisson, G, Le Cesne, A, Biron, P, Chauvin, F, Blay, J Y
Publicado 2003

Adaptive intrapatient dose escalation of cisplatin in combination with low-dose vp16 in patients with nonsmall cell lung cancer

por Schellens, J H M, Planting, ASTh, van Zandwijk, N, Ma, J, Maliepaard, M, van der Burg, M E L, de Boer-Dennert, M, Brouwer, E, van der Gaast, A, van den Bent, M J, Verweij, J
Publicado 2003

Early diagnosis of pancreatic cancer: neutrophil gelatinase-associated lipocalin as a marker of pancreatic intraepithelial neoplasia

por Moniaux, N, Chakraborty, S, Yalniz, M, Gonzalez, J, Shostrom, V K, Standop, J, Lele, S M, Ouellette, M, Pour, P M, Sasson, A R, Brand, R E, Hollingsworth, M A, Jain, M, Batra, S K
Publicado 2008

Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis

por Martin, B, Paesmans, M, Berghmans, T, Branle, F, Ghisdal, L, Mascaux, C, Meert, A-P, Steels, E, Vallot, F, Verdebout, J-M, Lafitte, J-J, Sculier, J-P
Publicado 2003

The new cardioprotector Monohydroxyethylrutoside protects against doxorubicin-induced inflammatory effects in vitro

por Abou El Hassan, M A I, Verheul, H M W, Jorna, A S, Schalkwijk, C, van Bezu, J, van der Vijgh, W J F, Bast, A
Publicado 2003

Severe intracellular magnesium and potassium depletion in patients after treatment with cisplatin

por Lajer, H, Bundgaard, H, Secher, N H, Hansen, H H, Kjeldsen, K, Daugaard, G
Publicado 2003

A phase II study of irinotecan plus chronomodulated oxaliplatin, 5-fluorouracil and folinic acid in advanced colorectal cancer patients

por Garufi, C, Bria, E, Vanni, B, Zappalà, A M R, Sperduti, I, Terzoli, E
Publicado 2003

Phase I/II study of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small-cell lung cancer

por Kiura, K, Ueoka, H, Segawa, Y, Tabata, M, Kamei, H, Takigawa, N, Hiraki, S, Watanabe, Y, Bessho, A, Eguchi, K, Okimoto, N, Harita, S, Takemoto, M, Hiraki, Y, Harada, M, Tanimoto, M
Publicado 2003

Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcγRI × anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer

por Repp, R, van Ojik, H H, Valerius, T, Groenewegen, G, Wieland, G, Oetzel, C, Stockmeyer, B, Becker, W, Eisenhut, M, Steininger, H, Deo, Y M, Blijham, G H, Kalden, J R, van de Winkel, J G J, Gramatzki, M
Publicado 2003

Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: long-term results of a prospective study

por Zeleniuch-Jacquotte, A, Shore, R E, Koenig, K L, Akhmedkhanov, A, Afanasyeva, Y, Kato, I, Kim, M Y, Rinaldi, S, Kaaks, R, Toniolo, P
Publicado 2004

Quantitative analysis of human kallikrein gene 14 expression in breast tumours indicates association with poor prognosis

por Yousef, G M, Borgoño, C A, Scorilas, A, Ponzone, R, Biglia, N, Iskander, L, Polymeris, M-E, Roagna, R, Sismondi, P, Diamandis, E P
Publicado 2002

A single-nucleotide polymorphism in the RAD51 gene modifies breast cancer risk in BRCA2 carriers, but not in BRCA1 carriers or noncarriers

por Kadouri, L, Kote-Jarai, Z, Hubert, A, Durocher, F, Abeliovich, D, Glaser, B, Hamburger, T, Eeles, R A, Peretz, T
Publicado 2004

Randomised controlled trial comparing single agent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based c...

por Buda, A, Floriani, I, Rossi, R, Colombo, N, Torri, V, Conte, P F, Fossati, R, Ravaioli, A, Mangioni, C
Publicado 2004

Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer

por Hussain, S A, Stocken, D D, Peake, D R, Glaholm, J G, Zarkar, A, Wallace, D M A, James, N D
Publicado 2004

Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials

por Cutsem, E Van, Hoff, P M, Harper, P, Bukowski, R M, Cunningham, D, Dufour, P, Graeven, U, Lokich, J, Madajewicz, S, Maroun, J A, Marshall, J L, Mitchell, E P, Perez-Manga, G, Rougier, P, Schmiegel, W, Schoelmerich, J, Sobrero, A, Schilsky, R L
Publicado 2004

Breast adenocarcinoma liver metastases, in contrast to colorectal cancer liver metastases, display a non-angiogenic growth pattern that preserves the stroma and lacks hypoxia

por Stessels, F, Van den Eynden, G, Van der Auwera, I, Salgado, R, Van den Heuvel, E, Harris, A L, Jackson, D G, Colpaert, C G, Van Marck, E A, Dirix, L Y, Vermeulen, P B
Publicado 2004

Capecitabine in hormone-resistant metastatic prostatic carcinoma – a phase II trial

por Morant, R, Bernhard, J, Dietrich, D, Gillessen, S, Bonomo, M, Borner, M, Bauer, J, Cerny, T, Rochlitz, C, Wernli, M, Gschwend, A, Hanselmann, S, Hering, F, Schmid, H-P
Publicado 2004

A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer

por Stoehlmacher, J, Park, D J, Zhang, W, Yang, D, Groshen, S, Zahedy, S, Lenz, H-J
Publicado 2004